Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HLX70 in healthy volunteers
NCT05429385Phase 1Withdrawn
- Sponsor
- Henlius
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of HLX70 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Henlius. Primary endpoints: Adverse Events, Serious Adverse Events, Infusion-Related Reactions up to 92 days and Dose Limiting Toxicity. Planned start Dec 2020; status: withdrawn.
02
Drugs
HLX70
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05429385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429385.